Avanamd Healthcare
Clinical Trial Phases
Clinical trials are essential for evaluating the safety, efficacy, and overall performance of investigational medicines before and after they become available to patients. At Avanamd Healthcare, we support clinical research through biostatistics, clinical data management, statistical programming, medical writing, and data quality oversight. Understanding the different phases of clinical trials helps research teams plan studies, evaluate results, and maintain reliable clinical data throughout the drug development process.
Safety and Tolerability
Phase I Clinical Trials
Phase I clinical trials primarily evaluate the safety and tolerability of an investigational medicine. Researchers assess how the medicine behaves in the body, determine appropriate dose ranges, and monitor potential side effects. These studies typically involve a small group of participants, often healthy volunteers, although some trials involve patients depending on the medicine and disease being studied.
Efficacy and Dose Evaluation
Phase II Clinical Trials
Phase II clinical trials explore the preliminary efficacy of an investigational medicine and further evaluate its safety. Researchers assess different doses, examine treatment responses, and collect additional information to help determine whether the medicine should proceed to larger studies.
Confirmatory Efficacy and Safety
Phase III Clinical Trials
Phase III clinical trials evaluate the efficacy and safety of an investigational medicine in larger participant populations. These studies often compare the treatment with an existing standard of care or placebo, where appropriate. The collected evidence helps establish the medicine's benefit-risk profile and supports regulatory submission and marketing authorization decisions.
Post-Marketing Surveillance
Phase IV Clinical Trials
Phase IV studies take place after a medicine has received marketing authorization. They help researchers monitor its long-term safety and effectiveness in broader patient populations, identify rare or previously unrecognized adverse reactions, and evaluate its performance in real-world settings.